Unlock KRAS G12C for lung cancer treatment decisions

2 Views

07/07/23

Webinar presenter, Anjen Chenn, MD, PhD, Medical Director, Center for Molecular Biology and Pathology, Discipline Director for Molecular Oncology, Labcorp, discusses the NCCN Guidelines® and the importance of KRAS G12C testing in NSCLC patients for a targeted therapy, KRAS G12C—a key emerging biomarker in non-small cell lung cancer (NSCLC), LUMAKRAS™—an approved treatment for NSCLC patients whose tumors harbor KRAS G12C mutations, and QIAGEN® therascreen® KRAS RGQ PCR Kit—an FDA-approved companion diagnostic to identify the KRAS G12C mutation. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast October 26, 2021.